An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2080

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: BEA 2180 BR
DRUG: Tiotropium Bromide
DRUG: Placebo

Sponsor

Boehringer Ingelheim